BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4282925)

  • 1. In vitro cytotoxicity of normal serum factor(s) on neuraminidase-treated Ehrlich ascites tumor cells and murine leukemia L 1210 cells.
    Sethi KK; Brandis H
    Z Immunitatsforsch Exp Klin Immunol; 1972 May; 143(4):426-9. PubMed ID: 4282925
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigenicity of Ehrlich ascites through neuraminidase treatment of cells.
    Sur P; Roy DK
    Indian J Exp Biol; 1979 Sep; 17(9):953-5. PubMed ID: 544474
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity of leukemia L1210 cells after neuraminidase treatment.
    Bekesi JG; St Arneault G; Walter L; Holland JF
    J Natl Cancer Inst; 1972 Jul; 49(1):107-18. PubMed ID: 4338766
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic cytotoxic effect of macrophages and normal mouse serum on neuraminidase-treated murine leukaemia cells.
    Sethi KK; Brandis H
    Eur J Cancer (1965); 1973; 9(11-12):809-19. PubMed ID: 4613554
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase.
    Bagshawe KD; Currie GA
    Nature; 1968 Jun; 218(5148):1254-5. PubMed ID: 5656653
    [No Abstract]   [Full Text] [Related]  

  • 6. A naturally occurring complement dependent human IgM macroglobulin inhibitory to Ehrlich ascites tumor cells.
    Goff MM; Armentrout SA
    J Clin Lab Immunol; 1982 Dec; 9(3):163-7. PubMed ID: 7166749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of syngeneic, allogeneic and xenogeneic complement with murine leukaemia and carcinoma cells in vitro [proceedings].
    Peeters P; Verloes R; Atassi G; Kanarek L
    Arch Int Physiol Biochim; 1979 Oct; 87(4):836-8. PubMed ID: 93935
    [No Abstract]   [Full Text] [Related]  

  • 8. [Transplantable ascitic tumor derived from a mouse with moloney sarcoma: tumorigenic, antigenic and virologic properties (author's transl)].
    Weiland E; Weiland F
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):151-61. PubMed ID: 4283271
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance to Ehrlich ascites tumor in a strain of dystrophic mice.
    Carry PJ; Prescott DM; Ogilvie GK
    Cancer Res; 1979 Jun; 39(6 Pt 1):2139-40. PubMed ID: 445411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantability and antigenicity of two sublines of the TA3 tumor.
    Sanford BH; Codington JF; Jeanloz RW; Palmer PD
    J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor virus-associated antigenicity of L-1210 murine leukemia cells.
    Kisielow P; Radzikowski C; Steuden J; Szkudlarek J; Krawczynski K
    Arch Immunol Ther Exp (Warsz); 1971; 19(6):789-99. PubMed ID: 4335186
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of macrophages in the cytotoxic killing of tumour cells in vitro. I. Primary immunization of lymphocytes in vitro for target cell killing and the mechanism of lymphocyte-macrophage cooperation.
    Zembala M; Ptak W; Hanczakowska M
    Immunology; 1973 Oct; 25(4):631-44. PubMed ID: 4356674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin.
    Buzzi S; Buzzi L
    Cancer Res; 1974 Dec; 34(12):3481-6. PubMed ID: 4429964
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural cell-mediated cytotoxicity in Ehrlich ascites tumor-bearing mice.
    Olinescu A; Hristescu S; Mazilu E
    Neoplasma; 1983; 30(2):147-52. PubMed ID: 6843720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
    Bekesi JG; St-Arneault G; Holland JF
    Cancer Res; 1971 Dec; 31(12):2130-2. PubMed ID: 5120303
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific and non-specific immunotherapy of Ehrlich Ascites Carcinoma in mice.
    Jakóbisiak M; Kańtoch M; Lasek W; Dobaczewska H; Obłakowski P
    Folia Biol (Krakow); 1982; 30(3-4):91-7. PubMed ID: 7166197
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase.
    Hughes RC; Palmer PD; Sanford BH
    J Immunol; 1973 Oct; 111(4):1071-80. PubMed ID: 4728677
    [No Abstract]   [Full Text] [Related]  

  • 20. Supression of growth of Ehrlich ascites tumor cells in mice pretreated with synthetic analogs of trehalose-6,6-dimycolate (cord factor).
    Yarkoni E; Bekierkunst A; Asselineau J; Toubiana R; Toubiana MJ; Lederer E
    J Natl Cancer Inst; 1973 Aug; 51(2):717-20. PubMed ID: 4765386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.